Rakovina Reports Preclinical Progress on Brain-Penetrant ATR Inhibitors

PUBT · 2d ago
Rakovina Reports Preclinical Progress on Brain-Penetrant ATR Inhibitors
  • Rakovina Therapeutics advanced its AI-designed kt-5000AI ATR inhibitor program with Variational AI toward development-candidate selection for potential brain cancer treatments.
  • Optimized compounds achieved sub-nanomolar potency, strong selectivity and a tenfold improvement in metabolic stability.
  • First-generation compounds demonstrated brain penetration in mice; studies assessing brain exposure in optimized compounds remain ongoing.
  • Discovery required 122 compounds, roughly two years and about US$1 million, versus modeled conventional costs of US$7.6 million over 4.5 years.
  • Lead optimization continues through year-end 2026; the program remains preclinical, with no final development candidate formally nominated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220530PRIMZONEFULLFEED9851051) on October 22, 2026, and is solely responsible for the information contained therein.